ABUS Arbutus Biopharma Corp

Price (delayed)

$4.85

Market cap

$959.56M

P/E Ratio

6.06

Dividend/share

N/A

EPS

$0.8

Enterprise value

$944.02M

?
Relative Growth: Rel. Growth: 44
Relative Strength: Rel. Strength: 61
Relative Valuation: Rel. Valuation: 93
Relative Profitability: Rel. Profitability: 100

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a ...

Highlights
ABUS's quick ratio has soared by 50% QoQ
The debt has declined by 27% year-on-year and by 7% since the previous quarter
Arbutus Biopharma's gross profit has decreased by 5% QoQ
The company's EPS fell by 4.8% QoQ

Key stats

What are the main financial stats of ABUS

ABUS stock price

How has the Arbutus Biopharma stock price performed over time
Intraday
-3.19%
1 week
-3.96%
1 month
-6.91%
1 year
8.74%
YTD
0.83%
QTD
1.04%

Financial performance

How have Arbutus Biopharma's revenue and profit performed over time
Revenue
$181.72M
Gross profit
$181.72M
Operating income
$147.03M
Net income
$153.05M
Gross margin
100%
Net margin
84.2%
The net margin has surged by 124% year-on-year
ABUS's operating margin has surged by 122% year-on-year
Arbutus Biopharma's gross profit has decreased by 5% QoQ
Arbutus Biopharma's revenue has decreased by 5% QoQ

Price vs fundamentals

How does ABUS's price correlate with its fundamentals

Growth

What is Arbutus Biopharma's growth rate over time

Valuation

What is Arbutus Biopharma stock price valuation
P/E
6.06
P/B
3.7
P/S
5.27
EV/EBIT
6.16
EV/EBITDA
6.16
EV/Sales
5.19
The company's EPS fell by 4.8% QoQ
ABUS's price to book (P/B) is 50% lower than its last 4 quarters average of 7.6 and 22% lower than its 5-year quarterly average of 4.9
The price to sales (P/S) is 86% lower than the 5-year quarterly average of 38.8 and 84% lower than the last 4 quarters average of 33.7
Arbutus Biopharma's revenue has decreased by 5% QoQ

Efficiency

How efficient is Arbutus Biopharma business performance
The company's return on sales has surged by 124% YoY
The ROIC has declined by 32% since the previous quarter
The ROE is down by 30% since the previous quarter
Arbutus Biopharma's return on assets has decreased by 27% QoQ

Dividends

What is ABUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABUS.

Financial health

How did Arbutus Biopharma financials performed over time
The company's total assets has surged by 165% YoY
The company's current ratio has surged by 50% QoQ
The debt is 99% smaller than the equity
ABUS's debt to equity has dropped by 83% year-on-year and by 50% since the previous quarter
The debt has declined by 27% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.